Cipla Limited — Amphotericin Exporter Profile
Indian Pharmaceutical Exporter · #8 for Amphotericin · $750.0K export value · DGFT Verified
Cipla Limited is the #8 Indian exporter of Amphotericin with $750.0K in export value and 15 verified shipments. Cipla Limited holds a 1.2% market share in Amphotericin exports across 4 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Amphotericin Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Amphotericin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CHILE | $300.0K | 6 | 66.4% |
| LIBYA | $75.7K | 2 | 16.8% |
| PARAGUAY | $50.0K | 1 | 11.1% |
| BRAZIL | $26.3K | 6 | 5.8% |
Cipla Limited exports Amphotericin to 4 countries. The largest destination is CHILE accounting for 66.4% of Cipla Limited's Amphotericin shipments, followed by LIBYA (16.8%) and PARAGUAY (11.1%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Amphotericin from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| INDOPHARMA S.A. | CHILE | $200.0K | 4 |
| INDOPHARMA S A | CHILE | $100.0K | 2 |
| TO THE ORDER OF NATIONAL CERTER FOR | LIBYA | $75.7K | 2 |
| PROSALUD FARMA S A | PARAGUAY | $50.0K | 1 |
| CIPLA BRASIL IMPORTADORA E DISTRIB | BRAZIL | $26.3K | 6 |
Cipla Limited supplies Amphotericin to 5 buyers globally. The largest buyer is INDOPHARMA S.A. (CHILE), followed by INDOPHARMA S A (CHILE) and TO THE ORDER OF NATIONAL CERTER FOR (LIBYA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Amphotericin Export Value and How Much Does Cipla Limited Contribute?
India exported $28.0M worth of Amphotericin through 1,226 shipments from 180 suppliers to 116 countries, serving 390 buyers globally. Cipla Limited contributes $750.0K to this total, accounting for 1.2% of India's Amphotericin exports. Cipla Limited ships Amphotericin to 4 countries through 5 buyers.
What Is the Average Shipment Value for Cipla Limited's Amphotericin Exports?
Cipla Limited's average Amphotericin shipment value is $50.0K per consignment, based on 15 shipments totaling $750.0K. The largest destination is CHILE (66.4% of Cipla Limited's Amphotericin exports).
How Does Cipla Limited Compare to Other Indian Amphotericin Exporters?
Cipla Limited ranks #8 among 180 Indian Amphotericin exporters with a 1.2% market share. The top 3 exporters are BHARAT SERUMS AND VACCINES LIMITED ($15.8M), EMCURE PHARMACEUTICALS LIMITED ($4.5M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($3.8M). Cipla Limited processed 15 shipments to 4 destination countries.
What Amphotericin Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHOSOME B LIPOSOMAL 50MG INJECTION AMPHOTERICIN B LIPOSOME 2412 PACK1X20 ML | $50.0K | 1 |
| PHOSOME B LIPOSOMAL 50MG INJECTION (AMPHOTERICIN B LIPOSOME) (1,744 Pack)(1 X 20 ML) | $50.0K | 1 |
| PHOSOME B LIPOSOMAL 50MG INJECTION (AMPHOTERICIN B LIPOSOME) (2362Pack)(1X 20ML/packs) | $50.0K | 1 |
| PHOSOME B LIPOSOMAL 50MG INJECTION (AMPHOTERICIN B LIPOSOME) (2369 Pack )(1 X 20 ML/PACKS) | $50.0K | 1 |
| PHOSOME B LIPOSOMAL 50MG INJECTION (AMPHOTERICIN B LIPOSOME) (2397 PACK) (1x20 ML) | $50.0K | 1 |
| PHOSOME 50 (AMPHOTERICIN B(LIPOSOMAL) 50MG VIAL) (1500 PACK)(20 ML) | $50.0K | 1 |
| ANFOTERICINA B LIPOSOMAL 50 MG. PSF (AMPHOTERICIN B(LIPOSOMAL)50MG INJECTION) (1416PACK) (1X50MG(20ML) | $50.0K | 1 |
| PHOSOME B LIPOSOMAL 50MG INJECTION AMPHOTERICIN B LIPOSOME 1 X 20 ML | $50.0K | 1 |
| PHOSOME 50 (AMPHOTERICIN B(LIPOSOMAL) 50MG VIAL) (305 PACK) (20 ML) | $25.7K | 1 |
| AMPHOTERICIN B LIPOSOMAL POWDER FOR SOLUTION FOR INFUSION 50 MG | $25.6K | 2 |
Cipla Limited exports 11 distinct Amphotericin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHOSOME B LIPOSOMAL 50MG INJECTION AMPHOTERICIN B LIPOSOME 2 with 1 shipments worth $50.0K.
How Does Cipla Limited Compare to Nearest Amphotericin Exporters?
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | EMCURE PHARMACEUTICALS LIMITED | $4.5M | 89 | 7 | $50.0K |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $3.8M | 76 | 6 | $50.0K |
| 8 | CIPLA LIMITED ★ | $750.0K | 15 | 4 | $50.0K |
| 6 | CARITAS HEALTHCARE PRIVATE LIMITED | $600.0K | 12 | 1 | $50.0K |
| 4 | JODAS EXPOIM PRIVATE LIMITED | $500.0K | 10 | 1 | $50.0K |
Cipla Limited ranks #8 among 180 Indian Amphotericin exporters. Average shipment value of $50.0K compared to the market average of $155.4K. The closest competitors by value are EMCURE PHARMACEUTICALS LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Which Indian Ports Ship Amphotericin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 352 | 28.7% |
| SAHAR AIR | 345 | 28.1% |
| Bombay Air | 119 | 9.7% |
| DELHI AIR | 65 | 5.3% |
| DELHI AIR CARGO ACC (INDEL4) | 62 | 5.1% |
| NHAVA SHEVA SEA (INNSA1) | 38 | 3.1% |
| Bombay Air Cargo | 31 | 2.5% |
| BANGALORE ACC (INBLR4) | 20 | 1.6% |
Geopolitical & Trade Policy Impact on Cipla Limited's Amphotericin Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Amphotericin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Amphotericin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Amphotericin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 15 individual customs records matching Cipla Limited exporting Amphotericin, covering 11 formulations to 4 countries via 5 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 116+ countries, 390+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Amphotericin Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Amphotericin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Amphotericin Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Amphotericin. For current shipment-level data, contact TransData Nexus.